Albumin (human) is a Blood Derivative owned by Grifols, and is involved in 14 clinical trials, of which 9 were completed, and 5 are ongoing.

Human albumin occurs naturally as the major protein component of blood. Albumin is a soluble, monomeric protein necessary for maintaining and regulating the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentration and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation. Albumin is essential for maintaining the oncotic pressure in the vascular system. A decrease in oncotic pressure due to a low albumin level allows fluid to leak out from the interstitial spaces into the peritoneal cavity, producing ascites. The benefits of albumin infusions in preventing the deterioration in renal function associated with large-volume paracentesis, spontaneous bacterial peritonitis, and established hepatorenal syndrome.

The revenue for Albumin (human) is expected to reach a total of $19.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Albumin (human) NPV Report.

Albumin (human) is currently owned by Grifols.

Albumin (human) Overview

Human Albumin (Albutein, Plasbumin, albuplan ) is obtained by fractionation of blood plasma. It is formulated as solution for intravenous route of administration. Albutein is indicated for the treatment of hypoalbuminemia, restoration and maintenance of circulating blood volume where it is shown a deficit of volume and use of a colloid is appropriate. Plasbumin is indicated for the treatment of adult respiratory distress syndrome, burns, hypovolemic shock, liver failure. Albutein was under development for kidney transplant.

It is under development for the treatment of amyotrophic lateral sclerosis, Alzheimer's disease, decompensated acute-on-chronic liver cirrhosis, hepatic encephalopathy, septic shock, uncomplicated ascites.

Grifols Overview

Grifols is a pharmaceutical and chemical manufacturing company engaged on enhancing the health and well-being of patients worldwide. It is focused on research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. Grifols offers biological materials for clinical trials, biotechnology research, manufacturing pharmaceutical and diagnostic products. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers its products to hospitals, pharmacies and healthcare professionals. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain.

The company reported revenues of (Euro) EUR4,933.1 million for the fiscal year ended December 2021 (FY2021), a decrease of 7.6% over FY2020. In FY2021, the company’s operating margin was 12.1%, compared to an operating margin of 18.7% in FY2020. In FY2021, the company recorded a net margin of 3.8%, compared to a net margin of 11.6% in FY2020. The company reported revenues of EUR1,542.9 million for the second quarter ended June 2022, an increase of 21.8% over the previous quarter.

Quick View – Albumin (human)

Report Segments
  • Innovator (NME)
Drug Name
  • Albumin (human)
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Dermatology
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Hematological Disorders
  • Immunology
  • Metabolic Disorders
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.